HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

P&G Healthcare Business Has $10 Bil. Potential – CEO Lafley

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

Procter & Gamble's healthcare unit could generate in excess of $10 bil. annually within a few years, according to CEO A.G. Lafley

You may also be interested in...



Novartis/P&G Enablex Deal Offers OTC Switch Option

Procter & Gamble is broadening its long-term Rx-to-OTC switch prospects with a co-promotion deal for Novartis' Enablex (darifenacin) extended-release tablets in the U.S

Prilosec OTC Continues To Gain Share Amid Advertising, Supply Pressures

Procter & Gamble says sales of Prilosec OTC will face difficult year-over-year comparisons in the current quarter, indicating that growth for the heartburn drug may be slowing

P&G Business Realignment Combines Healthcare With Baby, Family Units

Procter & Gamble will consolidate its health, baby and family care units as a single entity under new leadership as part of a strategic realignment announced May 19

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits

Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer

‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation

Probiotics And Cold Remedies Boost Recordati In 2023

See All
UsernamePublicRestriction

Register

RS128444

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By